Indeed, interventions that target atypical myelopoiesis by enhancing IRF-8 expression demonstrated to abrogate MDSC-mediated immunosuppression and to promote MDSCs differentiation in effector myeloid cells including DCs and mature neutrophils with anti-tumor activity (7–9). The gene discussed is IRF8; the disease is neoplasm.